Voyager Therapeutics, Inc. (NASDAQ:VYGR - Get Free Report) has been given an average rating of "Buy" by the nine analysts that are presently covering the company, MarketBeat Ratings reports. Eight investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $17.00.
A number of analysts recently commented on VYGR shares. Canaccord Genuity Group reaffirmed a "buy" rating and set a $14.00 price target on shares of Voyager Therapeutics in a research report on Thursday, November 14th. HC Wainwright reiterated a "buy" rating and set a $30.00 price target on shares of Voyager Therapeutics in a research note on Thursday, November 14th. Wedbush started coverage on shares of Voyager Therapeutics in a report on Friday, November 29th. They set an "outperform" rating and a $11.00 price objective on the stock. StockNews.com downgraded shares of Voyager Therapeutics from a "buy" rating to a "hold" rating in a report on Friday. Finally, Citigroup assumed coverage on shares of Voyager Therapeutics in a report on Monday, December 2nd. They set a "buy" rating and a $12.00 target price on the stock.
Read Our Latest Report on VYGR
Insider Activity
In other Voyager Therapeutics news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the company's stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $5.82, for a total transaction of $34,914.18. Following the completion of the sale, the insider now directly owns 86,001 shares in the company, valued at $500,525.82. This represents a 6.52 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 4.53% of the company's stock.
Hedge Funds Weigh In On Voyager Therapeutics
Several institutional investors and hedge funds have recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. lifted its position in Voyager Therapeutics by 64.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 10,489 shares of the company's stock valued at $61,000 after purchasing an additional 4,098 shares during the last quarter. Intech Investment Management LLC bought a new stake in Voyager Therapeutics during the 3rd quarter valued at $74,000. SG Americas Securities LLC purchased a new stake in Voyager Therapeutics during the 2nd quarter valued at $85,000. Victory Capital Management Inc. grew its holdings in Voyager Therapeutics by 14.5% in the 2nd quarter. Victory Capital Management Inc. now owns 12,892 shares of the company's stock worth $102,000 after acquiring an additional 1,630 shares during the last quarter. Finally, Hsbc Holdings PLC purchased a new position in shares of Voyager Therapeutics in the second quarter valued at about $128,000. 48.03% of the stock is currently owned by institutional investors.
Voyager Therapeutics Stock Performance
Shares of NASDAQ VYGR traded down $0.23 during trading on Tuesday, hitting $6.25. 321,182 shares of the company traded hands, compared to its average volume of 630,122. The business's fifty day moving average is $6.58 and its 200 day moving average is $7.14. Voyager Therapeutics has a fifty-two week low of $5.19 and a fifty-two week high of $11.72. The firm has a market capitalization of $341.41 million, a price-to-earnings ratio of 8.80 and a beta of 0.90.
Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.16) EPS for the quarter, topping analysts' consensus estimates of ($0.45) by $0.29. The firm had revenue of $24.63 million during the quarter, compared to analyst estimates of $12.63 million. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. During the same period in the previous year, the company posted ($0.59) EPS. On average, analysts predict that Voyager Therapeutics will post -0.89 EPS for the current year.
Voyager Therapeutics Company Profile
(
Get Free ReportVoyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.
Further Reading
Before you consider Voyager Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Voyager Therapeutics wasn't on the list.
While Voyager Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
